Treatment
Cytarabine clinical trials
We’re tracking 156 recruiting studies that include Cytarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT07651176Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy approaches for newly diagnosed AML
This study tests three different chemotherapy regimens (LDA, LHAA, and DA) in adults aged 18–65 with newly diagnosed acute myeloid leukemia (AML, a blood cancer). The goal is to find which approach works best and is safest for patients fit enough for intensive treatment.
Hangzhou, ZhejiangAges 18–65 - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT07651163Enrolling by invitationPhase 2/Phase 3
Comparing three chemotherapy regimens for newly diagnosed blood cancer
This trial tests three different chemotherapy regimens for adults 15–65 years old with newly diagnosed acute myeloid leukemia (AML)—a serious blood cancer. The goal is to see which treatment approach works best for patients with intermediate or high-risk disease who are fit enough for intensive chemotherapy.
Hangzhou, ZhejiangAges 15–65 - NCT06697327Enrolling by invitation
Testing a three-drug combo for newly diagnosed AML
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
Hefei, AnhuiAges 18–59 - NCT06099366RecruitingPhase 2
Chemo for standard-risk childhood leukemia
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
Seoul, Other (Non U.s.)Ages 1–9 - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Birmingham, AlabamaAges 18–59 - NCT03013998RecruitingPhase 2/Phase 3
Personalized treatment study for acute myeloid leukemia
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Phoenix, ArizonaAges 18 years+ - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT05805098RecruitingPhase 2/Phase 3
Testing Venetoclax with chemo for newly diagnosed AML
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Suzhou, JiangsuAges 18–60 - NCT06345365RecruitingPhase 3
MA+AZA for Newly Diagnosed AML
This trial tests a combination of two medicines (called MA+AZA) for people who have just been diagnosed with acute myeloid leukemia (AML). It aims to see if this treatment can help control the disease and improve outcomes.
Zhengzhou, HenanAges 18–75 - NCT06537843RecruitingPhase 2
Venetoclax, cytarabine and metformin for AML
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
BelémAges 18 years+ - NCT07763210RecruitingPhase 2
IT therapy for immune cell-related side effects after CAR T
This trial tests a new way to give treatment directly into the spinal fluid for a serious side effect of CAR T cell therapy called ICANS. It may help people with certain types of lymphoma who are getting standard CAR T therapy and experience this brain-related complication.
Nashville, TennesseeAges 18 years+ - NCT06621199RecruitingPhase 2
Three-drug combination for newly diagnosed AML in older adults
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hangzhou, ZhejiangAges 60–70 - NCT07739654RecruitingPhase 3
Modified chemotherapy combo for relapsed large b-cell lymphoma
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Lahore, Punjab ProvinceAges 18 years+ - NCT04275518RecruitingPhase 1
Trial for relapsed leukemia or risky MDS with new drug
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07451912RecruitingPhase 1/Phase 2
Venetoclax Combo for CEBPA-Mutated AML in Unfit Patients
This trial tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) for people with newly diagnosed AML that has a CEBPA gene mutation and who are not strong enough for standard intensive chemotherapy. The goal is to see if this gentler approach works well.
Suzhou, JiangsuAges 18 years+ - NCT06060782RecruitingPhase 1
Chemo combo for high-risk blood cancer transplant patients
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Zhuhai, GuangdongAges 18–65 - NCT07255872RecruitingPhase 2/Phase 3
BL-M11D1 plus chemo for newly diagnosed AML
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07232134RecruitingPhase 3
Treating AML in children with Down syndrome
This trial tests a treatment plan for children with Down syndrome who have been diagnosed with acute myeloid leukemia (AML) or a related bone marrow condition. The goal is to see how well the therapy works and to help guide doctors in choosing the best approach.
MoscowAges 1 day–18 years - NCT07228273RecruitingPhase 2
A new drug combo for AML and high-risk MDS
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
Portland, OregonAges 18–65 - NCT07187193RecruitingPhase 2
Low-dose chemo plus thalidomide for untreated LCH
This trial tests a combination of two drugs, low-dose cytarabine and thalidomide, for adults with Langerhans cell histiocytosis (LCH) that has not been treated before with systemic therapy. The goal is to see if this treatment is safe and effective for people with LCH in multiple body areas or multiple spots in one system.
BeijingAges 18–70 - NCT06946407Recruiting
Chemotherapy combination for brain lymphoma
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
ChangchunAges Up to 60 years
What Cytarabine is being studied for
Conditions with recruiting Cytarabine studies.
Common questions
- Are there clinical trials studying Cytarabine?
- Yes. Clin2 currently lists 156 recruiting studies that include Cytarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cytarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cytarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cytarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.